Integrative assessment of clinicopathological parameters and the expression of PD-L1, PD-L2 and PD-1 in tumor cells of retroperitoneal sarcoma.

Ki-67 leiomyosarcoma liposarcoma prognosis program cell death ligand-1 program cell death ligand-2 programmed cell death-1 retroperitoneal sarcoma surgery undifferentiated pleomorphic sarcoma

Journal

Oncology letters
ISSN: 1792-1074
Titre abrégé: Oncol Lett
Pays: Greece
ID NLM: 101531236

Informations de publication

Date de publication:
Nov 2020
Historique:
received: 20 05 2020
accepted: 04 08 2020
entrez: 21 9 2020
pubmed: 22 9 2020
medline: 22 9 2020
Statut: ppublish

Résumé

Evidence is limited regarding the immunologic profile and immune microenvironment of soft tissue sarcoma subtypes. The aim of the present study was to describe the clinical significance and prognostic implications of PD-L1, PD-L2, and PD-1 in patients with retroperitoneal sarcoma (RSar). In this retrospective, multicenter, collaborative study, medical charts were reviewed and the immunohistochemical staining results of resected tissue specimens from 51 patients with RSar were examined. Immunohistochemical staining was performed with primary antibodies against PD-L1, PD-L2, PD-1, and Ki-67. The correlations between the baseline clinical parameters and expression levels of the four molecules in sarcoma cells were evaluated, and their prognostic values after tumor resection were assessed. Dedifferentiated liposarcoma (41%), leiomyosarcoma (20%), and undifferentiated pleomorphic sarcoma (16%) were the three major types identified. Dedifferentiated liposarcoma and leiomyosarcoma showed higher levels of PD-L1 expression than did other sarcomas. The Spearman correlation analysis revealed that baseline serum lactate dehydrogenase levels were moderately and positively correlated with PD-L1 (P=0.02, r=0.41) and PD-L2 (P=0.006, r=0.47) expression. The median recurrence-free and disease-specific survival was 58 and 16 months, respectively, during the 29-month median follow-up after surgery. On univariate analysis, a higher expression level of PD-1 was associated with a higher risk of recurrence, whereas multivariate analyses revealed that independent predictors of recurrence-free and disease-specific survival indicated a high expression of Ki-67 (P=0.03; hazard ratio, 2.29 vs. low expression) and prognostic stage IIIB (P=0.04; hazard ratio, 5.11 vs. stage I-II), respectively. Findings of the current study provide novel insights about the prognostic value of PD-L1, PD-L2, and PD-1 expression in RSar. Serum lactate dehydrogenase levels constitute a potential predictor of PD-L1 and PD-L2 expression levels in RSar. Further investigations are needed to determine the immunologic landscape of RSar and provide a foundation for therapeutic intervention using immune checkpoint inhibitors.

Identifiants

pubmed: 32952659
doi: 10.3892/ol.2020.12052
pii: OL-0-0-12052
pmc: PMC7479533
doi:

Types de publication

Journal Article

Langues

eng

Pagination

190

Informations de copyright

Copyright: © Miyake et al.

Références

Sarcoma. 2015;2015:547460
pubmed: 25705114
Ann Surg Oncol. 2019 Jul;26(7):2286-2293
pubmed: 31065964
Jpn J Clin Oncol. 2019 Feb 1;49(2):103-107
pubmed: 30423153
Zhonghua Yi Xue Za Zhi. 2014 Apr 29;94(16):1241-4
pubmed: 24924889
Cancer Sci. 2019 Oct;110(10):3038-3048
pubmed: 31385405
World J Surg Oncol. 2016 Feb 24;14(1):43
pubmed: 26911364
Lancet Oncol. 2014 Apr;15(4):415-23
pubmed: 24618336
Ann Surg. 2004 Feb;239(2):244-50
pubmed: 14745333
J Clin Oncol. 2000 Aug;18(15):2888-93
pubmed: 10920137
Front Med (Lausanne). 2019 Jul 31;6:174
pubmed: 31417907
Cancers (Basel). 2019 Feb 14;11(2):
pubmed: 30769874
Lancet Oncol. 2016 Dec;17(12):e542-e551
pubmed: 27924752
Lancet Oncol. 2018 Mar;19(3):416-426
pubmed: 29370992
Oncotarget. 2017 Jul 11;8(35):59570-59580
pubmed: 28938660
Sci Rep. 2019 Apr 29;9(1):6605
pubmed: 31036901
JAMA Oncol. 2020 Mar 1;6(3):402-408
pubmed: 31971541
Radiol Oncol. 2020 Feb 29;54(1):14-21
pubmed: 32114526
Cancer. 2018 Oct 1;124(19):3819-3829
pubmed: 29723407
BMC Cancer. 2018 Sep 24;18(1):913
pubmed: 30249211
Cancer. 2017 Sep 1;123(17):3291-3304
pubmed: 28463396
J Surg Oncol. 2011 Apr;103(5):390-4
pubmed: 21400521
Iowa Orthop J. 2015;35:181-6
pubmed: 26361463
J Surg Res. 2012 Jan;172(1):123-30
pubmed: 20869082
J Clin Oncol. 1997 Jan;15(1):350-62
pubmed: 8996162
J Eur Acad Dermatol Venereol. 2020 Aug;34(8):1715-1721
pubmed: 31838771
Cancers (Basel). 2019 Mar 29;11(4):
pubmed: 30934955
Zhonghua Zhong Liu Za Zhi. 2018 Apr 23;40(4):258-263
pubmed: 29730911
Neoplasia. 2016 Oct;18(10):636-646
pubmed: 27690238
Lancet. 2012 May 19;379(9829):1879-86
pubmed: 22595799
BMC Surg. 2019 Jun 10;19(1):61
pubmed: 31182086

Auteurs

Makito Miyake (M)

Department of Urology, Nara Medical University, Kashihara, Nara 634-8522, Japan.

Yuki Oda (Y)

Department of Urology, Nara Medical University, Kashihara, Nara 634-8522, Japan.

Nobutaka Nishimura (N)

Department of Urology, Nara Medical University, Kashihara, Nara 634-8522, Japan.

Yosuke Morizawa (Y)

Department of Urology, Nara Medical University, Kashihara, Nara 634-8522, Japan.

Sayuri Ohnishi (S)

Department of Urology, Nara Medical University, Kashihara, Nara 634-8522, Japan.

Kinta Hatakeyama (K)

Department of Diagnostic Pathology, Nara Medical University, Kashihara, Nara 634-8522, Japan.

Tomomi Fujii (T)

Department of Diagnostic Pathology, Nara Medical University, Kashihara, Nara 634-8522, Japan.

Shunta Hori (S)

Department of Urology, Nara Medical University, Kashihara, Nara 634-8522, Japan.

Daisuke Gotoh (D)

Department of Urology, Nara Medical University, Kashihara, Nara 634-8522, Japan.

Yasushi Nakai (Y)

Department of Urology, Nara Medical University, Kashihara, Nara 634-8522, Japan.

Satoshi Anai (S)

Department of Urology, Nara Medical University, Kashihara, Nara 634-8522, Japan.

Kazumasa Torimoto (K)

Department of Urology, Nara Medical University, Kashihara, Nara 634-8522, Japan.

Shinji Tsukamoto (S)

Department of Orthopedic Surgery, Nara Medical University, Kashihara, Nara 634-8522, Japan.

Hiromasa Fujii (H)

Department of Orthopedic Surgery, Nara Medical University, Kashihara, Nara 634-8522, Japan.

Akira Kido (A)

Department of Orthopedic Surgery, Nara Medical University, Kashihara, Nara 634-8522, Japan.

Kanya Honoki (K)

Department of Orthopedic Surgery, Nara Medical University, Kashihara, Nara 634-8522, Japan.

Yoshiaki Matsumura (Y)

Department of Urology, Nara Prefecture General Medical Center, Nara 630-8581, Japan.

Eijiro Okajima (E)

Department of Urology, Nara City Hospital, Nara 630-8305, Japan.

Nobumichi Tanaka (N)

Department of Urology, Nara Medical University, Kashihara, Nara 634-8522, Japan.
Department of Prostate Brachytherapy, Nara Medical University, Kashihara, Nara 634-8522, Japan.

Kiyohide Fujimoto (K)

Department of Urology, Nara Medical University, Kashihara, Nara 634-8522, Japan.

Classifications MeSH